• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向放射治疗的放射性药物化学,第4部分:在高活度和高辐射剂量下进行砹标记以产生α粒子的策略。

Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for At labeling at high activities and radiation doses of At α-particles.

作者信息

Pozzi Oscar R, Zalutsky Michael R

机构信息

Department of Radiology, Duke University Medical Center, Durham, NC, 27710, USA.

出版信息

Nucl Med Biol. 2017 Mar;46:43-49. doi: 10.1016/j.nucmedbio.2016.11.009. Epub 2016 Dec 10.

DOI:10.1016/j.nucmedbio.2016.11.009
PMID:28013121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5285439/
Abstract

INTRODUCTION

Alpha particles are radiation of high energy and short range, properties that can lead to radiolysis-mediated complications in labeling chemistry at the high radioactivity levels required for clinical application. In previous papers in this series, we have shown that radiation dose has a profound effect on the astatine species that are present in the labeling reaction and their suitability for the synthesis of N-succinimidyl 3-[At]astatobenzoate. The purpose of this study was to evaluate the effects of adding N-chlorosuccinimide (NCS) to the methanol solution used for initial isolation of At after distillation, a process referred to as At stabilization, on At chemistry after exposure to high radiation doses.

METHODS

High performance liquid chromatography was used to evaluate the distribution of At species present in methanol in the 500-65,000Gy radiation dose range and the synthesis of SAB from N-succinimidyl 3-(tri-n-butylstannyl)benzoate in the 500-120,000Gy radiation dose range using different At timeactivity combinations under conditions with/without At stabilization.

RESULTS

In the absence of NCS stabilization, a reduced form of astatine, At(2), increased with increasing radiation dose, accounting for about half the total activity by about 15,000Gy, while with stabilization, At(2) accounted for <10% of At activity even at doses >60,000Gy. SAB yields without stabilization rapidly declined with increasing dose, falling to ~20% at about 5000Gy while with stabilization, yields >80% were obtained with At solutions stored for more than 23h and receiving radiation doses >100,000Gy.

CONCLUSIONS

Adding NCS to the methanol solution used for initial isolation of At is a promising strategy for countering the deleterious effects of radiolysis on At chemistry.

ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE

This strategy could facilitate the ability to perform At labeling at sites remote from its production and at the high activity levels required for clinical applications.

摘要

引言

α粒子是一种高能且射程短的辐射,在临床应用所需的高放射性水平下,这些特性可能会在标记化学过程中导致辐射分解介导的并发症。在本系列的前几篇论文中,我们已经表明,辐射剂量对标记反应中存在的砹物种及其对N - 琥珀酰亚胺基3 - [At] 砹苯甲酸酯合成的适用性有深远影响。本研究的目的是评估在蒸馏后用于初始分离砹的甲醇溶液中添加N - 氯代琥珀酰亚胺(NCS)(该过程称为砹稳定化)对高辐射剂量照射后砹化学性质的影响。

方法

使用高效液相色谱法评估在500 - 65,000Gy辐射剂量范围内甲醇中存在的砹物种分布,以及在有/无砹稳定化条件下,使用不同的砹时间 - 活度组合,在500 - 120,000Gy辐射剂量范围内由N - 琥珀酰亚胺基3 - (三正丁基锡基)苯甲酸酯合成SAB的情况。

结果

在没有NCS稳定化的情况下,还原形式的砹At(2)随着辐射剂量的增加而增加,在约15,000Gy时约占总活度的一半,而在有稳定化的情况下,即使在剂量>60,000Gy时,At(2)也占砹活度的<10%。没有稳定化时,SAB产率随着剂量增加迅速下降,在约5000Gy时降至约20%,而在有稳定化的情况下,对于储存超过23小时且接受辐射剂量>100,000Gy的砹溶液,产率>80%。

结论

在用于初始分离砹的甲醇溶液中添加NCS是对抗辐射分解对砹化学性质有害影响的一种有前景的策略。

知识进展及对患者护理的意义

该策略可以促进在远离其生产地点且在临床应用所需的高活度水平下进行砹标记的能力。

相似文献

1
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for At labeling at high activities and radiation doses of At α-particles.靶向放射治疗的放射性药物化学,第4部分:在高活度和高辐射剂量下进行砹标记以产生α粒子的策略。
Nucl Med Biol. 2017 Mar;46:43-49. doi: 10.1016/j.nucmedbio.2016.11.009. Epub 2016 Dec 10.
2
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.靶向放射治疗的放射性药物化学,第3部分:α粒子对(211)砹化学行为的辐射分解效应
J Nucl Med. 2007 Jul;48(7):1190-6. doi: 10.2967/jnumed.106.038505. Epub 2007 Jun 15.
3
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.靶向放射治疗的放射性药物化学,第2部分:211Atα粒子的辐射分解效应影响N-琥珀酰亚胺基3-211At-astatobenzoate的合成。
J Nucl Med. 2005 Aug;46(8):1393-400.
4
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.靶向放射治疗的放射性药物化学,第1部分:溶剂对211Atα粒子导致的放射性卤化前体降解的影响。
J Nucl Med. 2005 Apr;46(4):700-6.
5
Labeling Monoclonal Antibody with α-emitting At at High Activity Levels via a Tin Precursor.通过锡前体以高比活度对单克隆抗体进行α放射性标记。
Cancer Biother Radiopharm. 2020 Sep;35(7):511-519. doi: 10.1089/cbr.2019.3204. Epub 2020 Feb 28.
6
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.实现[氬]-211 临床试验:化学基础设施。
Cancer Biother Radiopharm. 2020 Aug;35(6):425-436. doi: 10.1089/cbr.2019.3055. Epub 2020 Feb 20.
7
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.生物分子的自动化砹化——迈向多中心临床试验的垫脚石。
Sci Rep. 2015 Jul 14;5:12025. doi: 10.1038/srep12025.
8
Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.用砹-211 进行靶向放射性核素治疗:阿斯塔酸苯酯缀合物的氧化脱卤。
Sci Rep. 2017 May 31;7(1):2579. doi: 10.1038/s41598-017-02614-2.
9
Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.靶向 α 粒子治疗的进展。我们从体内发生器中了解到的放射性核素发射。
Molecules. 2018 Mar 5;23(3):581. doi: 10.3390/molecules23030581.
10
Development of a preclinical Rn/At generator system for targeted alpha therapy research with At.用于砹靶向α治疗研究的临床前镭/砹发生器系统的开发。
Nucl Med Biol. 2017 May;48:31-35. doi: 10.1016/j.nucmedbio.2017.01.011. Epub 2017 Jan 29.

引用本文的文献

1
Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.砹-211放射性标记化学:从基础到高级生物应用
EJNMMI Radiopharm Chem. 2024 Oct 4;9(1):69. doi: 10.1186/s41181-024-00298-4.
2
A third generation PSMA-targeted agent [At]YF2: Synthesis and in vivo evaluation.第三代 PSMA 靶向配体 [At]YF2:合成与体内评价。
Nucl Med Biol. 2024 Jul-Aug;134-135:108916. doi: 10.1016/j.nucmedbio.2024.108916. Epub 2024 May 1.
3
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.

本文引用的文献

1
(211)At-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds.用于α免疫疗法的砹标记剂:关于砹-试剂键的体内稳定性
Eur J Med Chem. 2016 Jun 30;116:156-164. doi: 10.1016/j.ejmech.2016.03.082. Epub 2016 Mar 29.
2
Scrutinizing "Invisible" astatine: A challenge for modern density functionals. scrutiny 意为“仔细检查;细看”,因此“Scrutinizing “Invisible” astatine”可译为“仔细研究‘无形’砹”。“astatine”是一种人工合成的放射性化学元素,其化学符号为 At,中文名为砹。 综上,译文为“仔细研究‘无形’砹:现代密度泛函理论面临的挑战。”
J Comput Chem. 2016 Jun 5;37(15):1345-54. doi: 10.1002/jcc.24326. Epub 2016 Apr 5.
3
Investigation of astatine(III) hydrolyzed species: experiments and relativistic calculations.
用于神经母细胞瘤的α粒子放射药物治疗的[211At]meta-替替苯胍([211At]MABG)的临床前开发。
Clin Cancer Res. 2022 Sep 15;28(18):4146-4157. doi: 10.1158/1078-0432.CCR-22-0400.
4
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.关于使用DNA修复抑制剂作为胶质母细胞瘤成像和放射性核素治疗工具的观点。
Cancers (Basel). 2022 Apr 3;14(7):1821. doi: 10.3390/cancers14071821.
5
Synthesis of [At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution.通过水溶液中的二羟基硼基-砹取代反应合成[At]4-砹-L-苯丙氨酸。
Sci Rep. 2021 Jun 21;11(1):12982. doi: 10.1038/s41598-021-92476-6.
6
Production, purification and availability of At: Near term steps towards global access.生产、纯化和供应 At:全球可及性的近期步骤。
Nucl Med Biol. 2021 Sep-Oct;100-101:12-23. doi: 10.1016/j.nucmedbio.2021.05.007. Epub 2021 Jun 10.
7
Labeling Monoclonal Antibody with α-emitting At at High Activity Levels via a Tin Precursor.通过锡前体以高比活度对单克隆抗体进行α放射性标记。
Cancer Biother Radiopharm. 2020 Sep;35(7):511-519. doi: 10.1089/cbr.2019.3204. Epub 2020 Feb 28.
8
Towards elucidating the radiochemistry of astatine - Behavior in chloroform.探索砹的放射化学 - 氯仿中的行为。
Sci Rep. 2019 Nov 4;9(1):15900. doi: 10.1038/s41598-019-52365-5.
9
Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio-Crosslinking.多功能点击试剂用于快速生物正交锝标记和放射性交联。
Chempluschem. 2019 Jul;84(7):775-778. doi: 10.1002/cplu.201900114. Epub 2019 Apr 4.
[氬(III)水解物种的研究:实验和相对论计算。]
J Phys Chem A. 2013 Mar 7;117(9):1983-90. doi: 10.1021/jp3099413. Epub 2013 Feb 20.
4
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.211砹和223镭在靶向α粒子放射治疗中的应用。
Curr Radiopharm. 2011 Oct;4(4):283-94. doi: 10.2174/1874471011104040283.
5
Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides.用发射α粒子的放射性核素进行放射性标记时的化学和放射化学考量。
Curr Radiopharm. 2011 Jul;4(3):214-47. doi: 10.2174/1874471011104030214.
6
Astatine standard redox potentials and speciation in acidic medium.砹的标准氧化还原电位和酸性介质中的形态。
J Phys Chem A. 2010 Jan 14;114(1):576-82. doi: 10.1021/jp9077008.
7
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.卵巢癌患者的腹腔内α粒子放射免疫疗法:(211)At-MX35 F(ab')2的药代动力学和剂量测定——一项I期研究
J Nucl Med. 2009 Jul;50(7):1153-60. doi: 10.2967/jnumed.109.062604. Epub 2009 Jun 12.
8
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.发射α粒子的砹-211的临床经验:用砹-211标记的嵌合抗腱生蛋白单克隆抗体81C6治疗复发性脑肿瘤患者。
J Nucl Med. 2008 Jan;49(1):30-8. doi: 10.2967/jnumed.107.046938. Epub 2007 Dec 12.
9
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.靶向放射治疗的放射性药物化学,第3部分:α粒子对(211)砹化学行为的辐射分解效应
J Nucl Med. 2007 Jul;48(7):1190-6. doi: 10.2967/jnumed.106.038505. Epub 2007 Jun 15.
10
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.靶向放射治疗的放射性药物化学,第2部分:211Atα粒子的辐射分解效应影响N-琥珀酰亚胺基3-211At-astatobenzoate的合成。
J Nucl Med. 2005 Aug;46(8):1393-400.